Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of IV Eptinezumab in Adolescents (12-17 years) for the Preventive Treatment of Chronic Migraine

Grants and Contracts Details

StatusActive
Effective start/end date1/26/221/11/25

Funding

  • H. Lundbeck A/S: $43,922.00